Brief: Seelos Therapeutics Doses First Patient In A Registrational Phase Ii/Iii Study Of Sls-005 In Spinocerebellar Ataxia
25/10/2022 13:40
Oct 25 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS DOSES FIRST PATIENT IN A
REGISTRATIONAL
PHASE II/III STUDY OF SLS-005 IN SPINOCEREBELLAR ATAXIA
Source text for Eikon: ID:nPncg7B4Ka
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio